The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so in most of indiv individuals what if you look at the distribution of lpa in the population it's really skewed towards the null so it means that there's a lot of patient most individuals have very low levels of of lpa and there's some individual as we as we mentioned 15 to 20 percent that have high lpa levels now in individuals of african ancestry it's it's a more like a gaussian distribution so um so that's one of the reasons why they have higher lpa
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
it's important to recognize this heterogeneity in the multiple isoforms because this accounts for some of the differences in cardiovascular risk that we see by race ethnicity with higher hypertel a levels being seen in black and South Asian individuals compared to whites white individuals